Economy/Home · Economy

Chong Kun Dang Bio Files for Approval of Botulinum Toxin 'Tyemvers' in China... Demonstrates Non-Inferiority to Botox in Glabellar Line Improvement

Chong Kun Dang Bio announced in a regulatory filing on the 14th that it has submitted an application for product approval in China for its botulinum toxin formulation 'Tyemvers for Injection, 100units (Clostridium botulinum toxin Type A).' The target indication is moderate to severe glabellar lines

Oseong Kwon
Staff Reporter
6 min read
Chong Kun Dang Bio Files for Approval of Botulinum Toxin 'Tyemvers' in China... Demonstrates Non-Inferiority to Botox in Glabellar Line Improvement
CBC News

Chong Kun Dang Bio announced in a regulatory filing on the 14th that it has submitted an application for product approval in China for its botulinum toxin formulation 'Tyemvers for Injection, 100units (Clostridium botulinum toxin Type A).'

The target indication is moderate to severe glabellar lines. The application was filed on August 14, 2026, and the regulatory authority is China's National Medical Products Administration (NMPA).

[Clinical Trial Design]

According to the company, the clinical trial was conducted with the primary objective of comparatively evaluating the efficacy of a single administration of CU-20101 against Botox in improving moderate to severe glabellar lines. As secondary objectives, safety and immunogenicity following single administration were compared with Botox, while efficacy, safety, and immunogenicity were evaluated following repeated administration.

The clinical trial was conducted from June 26, 2024, to November 20, 2025.

[Efficacy Evaluation... Non-Inferiority to Botox Demonstrated]

The glabellar line improvement rate at four weeks after a single administration was 74.0% (205/277 patients) in the test group (CU-20101) and 74.9% (206/275 patients) in the control group (Botox). The difference in improvement rates between the two groups was -1.5%, with a p-value of 0.7637.

The lower bound of the two-sided 95% confidence interval was -8.6%, which was higher than the pre-defined non-inferiority margin of -12%, thereby demonstrating the non-inferiority of CU-20101 to Botox, the company said.

[Safety Evaluation]

The incidence of all adverse events after single administration was 52.9% (147/278 patients) in the test group and 50.9% (140/275 patients) in the control group. Adverse drug reactions for which a causal relationship could not be ruled out were 2.5% (7/278 patients) and 2.9% (8/275 patients), respectively, while serious adverse events were 1.1% (3/278 patients) and 2.2% (6/275 patients), respectively. There were no serious adverse drug reactions for which a causal relationship could not be ruled out.

Upon repeated administration of CU-20101, the incidence of adverse events was 38.1% (149/391 patients) in Cycle 2, 23.9% (38/159 patients) in Cycle 3, and 36% (9/25 patients) in Cycle 4. Adverse drug reactions were 1.3%, 1.9%, and 0%, respectively, and there were no serious adverse drug reactions.

[Launch Plans and Risk Factors]

Chong Kun Dang Bio plans to launch the product in the region following approval from the NMPA.

However, the company stated that it has not yet been confirmed whether the product approval application has been formally accepted for review. It explained that between submission and formal acceptance, requests for supplementary data or rejection of the application may occur, and that the product approval application does not guarantee a final approval decision by the regulatory authority. Accordingly, the company disclosed that commercialization plans may be modified or abandoned depending on the outcome of the review.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.